Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS
Posted innews Psychiatry

Large Phase 3 Trials Show No Cognitive Benefit with Iclepertin in Schizophrenia — What the CONNEX Programme Teaches Us About Treating CIAS

Three multinational phase 3 trials found no clinically meaningful cognitive benefit of the GlyT1 inhibitor iclepertin versus placebo in schizophrenia, though the drug was well tolerated. Results highlight methodological and biological challenges in developing treatments for cognitive impairment associated with schizophrenia.
Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials
Posted inPsychiatry Specialties

Evaluating the Role of Behavioral Therapy in Enhancing Buprenorphine Treatment Outcomes for Opioid Use Disorder: Insights from a Secondary Analysis of Four Randomized Clinical Trials

A secondary analysis of four randomized trials reveals that additional behavioral therapy does not significantly improve opioid abstinence, retention, or functional outcomes when added to buprenorphine and medical management in opioid use disorder treatment.
Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us
Posted inClinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us

Recent randomized and mechanistic studies provide a nuanced view: metformin shows plausible anti‑aging mechanisms and microbiome‑linked cognitive associations, but randomized trials report no clear anti‑cancer or anti‑senescence effects in humans to date.
Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases
Posted inAllergy & Immunology Clinical Updates Family Medicine & Nutrition news Specialties

Low-Dose Interleukin-2: Unlocking Immune Modulation Across Autoimmune, Neurodegenerative, Metabolic, Transplant, and Inflammatory Diseases

Low-dose IL-2 immunotherapy demonstrates broad, disease-modifying effects by selectively expanding regulatory T cells (Tregs), offering a promising strategy across diverse diseases including autoimmunity, neurodegeneration, metabolic dysfunction, transplantation, and inflammatory disorders.